Research Program: Hematologic Malignancies

恶性血液病项目 恶性血液病项目的目标是更好地了解和改进 对这类疾病的治疗。重点关注四个方面：(1)加深了解 血液病的生物学基础；(2)利用这种认识发展更好的非 移植疗法；(3)发现克服目前造血细胞局限性的新方法 移植；以及(4)利用这些发现改进造血细胞的实际应用 移植。恶性血液病计划目前有75名成员，来自11个部门和3个 机构。73名成员(97%)拥有同行评审的资金或是一项 临床试验。恶性血液病计划目前有2430万美元的赠款资金(直接美元) 其中1690万美元来自同行评审，690万美元(40%)来自NCI。年共发表论文1218篇 上一个授权期。27%是方案内方案，35%是方案间方案，19%是方案间方案 制度性的。2012年，148,040名美国人被诊断出患有血液系统恶性肿瘤，导致54,380人 死亡，使这些恶性肿瘤成为仅次于肺癌的第二大癌症死亡原因 (160,340)，超过了结肠癌(51,690)、乳房(39,920)、胰腺(37,390)的死亡人数； 前列腺癌(28,170)。我们节目之前的工作增进了我们对这一群体的了解 疾病，特别是髓系恶性肿瘤，导致了筛查基因的新方法 新的治疗方法，改善了对疾病进展的监测。我们的研究结果 也使人们更好地理解了造血细胞移植问题背后的科学 并提供了克服其中一些问题的方法，从而提高了治愈率。本组织的成员 该计划还监督着非常繁忙的临床服务，仅在2013年就照顾了802名新患者，其中466人 (58%)在临床试验中接受治疗。

Hematologic Malignancies Program The goal of the Program in Hematologic Malignancies is to develop a better understanding and improved treatments for this group of diseases. Four areas of focus predominate: (1) Developing a deeper understanding of the biologic basis of hematologic malignancies; (2) Using this understanding to develop better non- transplant therapies; (3) Discovering novel methods to overcome the current limitations of hematopoietic cell transplantation; and (4) Using these discoveries to improve the actual practice of hematopoietic cell transplantation. The Hematologic Malignancies program currently has 75 members from 11 departments and 3 institutions. Seventy-three Members (97%) have peer-reviewed funding or are the Principal Investigator on a clinical trial. The Hematologic Malignancies program currently has $24.3M in grant funding (direct dollars) of which $16.9M is peer-reviewed and $6.9M (40%) is from NCI. The Program published a total of 1218 papers in the previous grant period. 27% were intra-programmatic, 35% were inter-programmatic and 19% were inter- institutional. In 2012, 148,040 Americans were diagnosed with a hematologic malignancy, resulting in 54,380 deaths, making these malignancies collectively the second leading cause of cancer death after lung cancer (160,340), and exceeding in aggregate the deaths from colon (51,690), breast (39,920) pancreas (37,390), and prostate cancer (28,170). Previous work from our program has improved our understanding of this group of diseases, particularly the myeloid malignancies, leading to new approaches to screening for genetic abnormalities, improved monitoring of disease progression and novel therapeutics. Results from our studies have also led to a better understanding of the science behind problems of hematopoietic cell transplantation and provided methods to overcome some of these problems leading to improved cure rates. Members of this program also oversee a very busy clinical service, caring for 802 new patients in 2013 alone, of which 466 (58%) were treated on clinical trials.